🇺🇸 FDA
Pipeline program

ALLO-501

ALLO-501-201

Phase 1 gene_therapy completed

Quick answer

ALLO-501 for Relapsed/Refractory Large B Cell Lymphoma is a Phase 1 program (gene_therapy) at Allogene Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Allogene Therapeutics
Indication
Relapsed/Refractory Large B Cell Lymphoma
Phase
Phase 1
Modality
gene_therapy
Status
completed

Clinical trials